An RNA aptamer-based biomarker platform demonstrates high soluble CD25 occupancy by IL2 in the serum of follicular lymphoma patients

Por Veeramani, Suresh, Blackwell, Sue E., Thiel, William H., Yang, Zhi-Zhang, Ansell, Stephen M., Giangrande, Paloma H., Weiner, George J.
Publicado no Cancer Immunol Res (2019)

B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation

Por Jahrsdörfer, Bernd, Blackwell, Sue E., Wooldridge, James E., Huang, Jian, Andreski, Melinda W., Jacobus, Laura S., Taylor, Christiana M., Weiner, George J.
Publicado em 2006

Antibody opsonization of a TLR9-agonist-containing virus-like particle enhances in situ immunization

Por Lemke-Miltner, Caitlin D., Blackwell, Sue E., Yin, Chaobo, Krug, Anna E., Morris, Aaron J., Krieg, Arthur M., Weiner, George J.
Publicado no J Immunol (2020)

Three Steps to Breaking Immune Tolerance to Lymphoma: A Microparticle Approach

Por Makkouk, Amani, Joshi, Vijaya B, Lemke, Caitlin D, Wongrakpanich, Amaraporn, Olivier, Alicia K, Blackwell, Sue E, Salem, Aliasger K, Weiner, George J
Publicado no Cancer Immunol Res (2015)

B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21

Por Hagn, Magdalena, Blackwell, Sue E., Beyer, Thamara, Ebel, Verena, Fabricius, Dorit, Lindner, Stefanie, Stilgenbauer, Stefan, Simmet, Thomas, Tam, Constantine, Neeson, Paul, Trapani, Joseph A., Schrezenmeier, Hubert, Weiner, George J., Jahrsdörfer, Bernd
Publicado em 2014

Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion

Por Jahrsdörfer, Bernd, Vollmer, Angelika, Blackwell, Sue E., Maier, Julia, Sontheimer, Kai, Beyer, Thamara, Mandel, Birgit, Lunov, Oleg, Tron, Kyrylo, Nienhaus, G. Ulrich, Simmet, Thomas, Debatin, Klaus-Michael, Weiner, George J., Fabricius, Dorit
Publicado em 2010

Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab is Effective...

Por Zent, Clive S., Taylor, Ronald P., Lindorfer, Margaret A., Beum, Paul V., LaPlant, Betsy, Wu, Wenting, Call, Timothy G., Bowen, Deborah A., Conte, Michael J., Frederick, Lori A., Link, Brian K., Blackwell, Sue E., Veeramani, Suresh, Baig, Nisar A., Viswanatha, David S., Weiner, George J., Witzig, Thomas E.
Publicado no Am J Hematol (2014)